The regulator has already issued more recalls in the first half of 2014 than it has over the past nine years.
The new rules are expected to do away with the haphazard nature of facility inspections.
It's the generics maker's second recall of 2014.
The drugmaker is pulling its US marketing application for the anemia drug.
The US-only recall amounts to less than 1% of the company's inventory.
The company beat consensus estimates, with particular sales strengths from its pharmaceuticals division.
1,100 workers will lose their jobs at a plant with a history of around 40 recalls.
GSK and Astellas kick off the race for a new anemia treatment; Orexigen's CEO joins PhRMA; BMS and Merck team up in a hep.-C clinical trial; Novartis lands glaucoma approval; Ireland starts naming preferred drugs; Novo has new New Jersey digs; Vertex releases promising data for new cystic fibrosis treatment.
A buyout offer upsets Elan's post-Tysabri plans, Takeda and Affymax recall Omontys.
CEO Alex Gorsky said OTC brands are coming back. Meanwhile, pharmaceutical sales provided ballast to the year's numbers.
J&J is pushing back hard against a Wall Street Journal article suggesting that a pair of retirements and a promotion are part of a corporate shakeup of its recall-plagued McNeil Consumer Healthcare division.
- Guidemark Health merges with three companies to form new agency
- Five things for pharma marketers to know: Monday, October 17, 2016
- Five things for pharma marketers to know: Thursday, October 20, 2016
- Five things for pharma marketers to know: Tuesday, October 18, 2016
- Five things for pharma marketers to know: Wednesday, October 19, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy
- If Roche's Ocrevus is approved, the already competitive MS market will gain another player
- Top 25 neurology products, based on 2016 sales forecasts
- New science drives biopharma interest in neurological conditions
- J&J exec calls California pricing measure 'misguided'
- Five things for pharma marketers to know: Monday, October 24, 2016